Paper Details

  1. Home
  2. Paper Details

Relative Efficacy of Systemic Treatments for Patients with Advanced Hepatocellular Carcinoma According to Viral Status: A Systematic Review and Network Meta-Analysis.

Author: ChoJinhyun, KimJinchul, LeeMoon Hee, LimJoo Han, ParkJisun

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

A Bayesian network meta-analysis of 16 trials involving 6,410 patients with advanced hepatocellular carcinoma (HCC) found that lenvatinib was more efficacious than sorafenib in both the hepatitis B virus (HBV) and hepatitis C virus (HCV) subgroups for first-line treatment. Regorafenib was more effective than placebo in the HBV subgroup for second-line therapy.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Several clinical trials that tested the efficacy of systemic treatments for advanced hepatocellular carcinoma (HCC) showed a tendency that patients with hepatitis B virus (HBV) and hepatitis C virus (HCV) infection had different survival benefits from targeted agents. OBJECTIVE: The obj...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s11523-019-00651-7

データ提供：米国国立医学図書館（NLM）

Targeting Hepatocellular Carcinoma: A Tailored Approach Based on Viral Status

Hepatocellular carcinoma (HCC) is a type of liver cancer, and its treatment can be complex. This study investigates the relative efficacy of systemic treatments for advanced HCC, focusing on the impact of viral status, specifically hepatitis B virus (HBV) and hepatitis C virus (HCV) infection. The researchers conducted a systematic review and network meta-analysis to compare the survival benefits of different targeted therapies in patients with HBV or HCV infection.

A Personalized Approach to HCC Treatment

The study found that the efficacy of systemic targeted therapies for advanced HCC varied depending on the viral status of the patient. Lenvatinib emerged as the most effective agent for both HBV and HCV subgroups, offering a potential solution for this challenging disease.

Understanding the Importance of Viral Status

This research highlights the importance of considering viral status when choosing treatment options for HCC. Tailoring treatment strategies based on the specific viral infection can improve outcomes and enhance the effectiveness of therapies.

Dr.Camel's Conclusion

You know, just as different desert ecosystems require specific adaptations, HCC treatment requires a personalized approach. This research shows how understanding viral status can guide treatment decisions and improve the chances of survival for patients with this challenging disease.

Date :
  1. Date Completed 2020-04-01
  2. Date Revised 2020-04-01
Further Info :

Pubmed ID

31290003

DOI: Digital Object Identifier

10.1007/s11523-019-00651-7

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.